Position of the Transparency Council – Ontozry (cenobamat)
At its meeting on 16 August 2022 the Transparency Council adopted Position No. 75/2022 on the evaluation of the drug Ontozry (cenobamat) for the indication: supportive therapy of focal seizures undergoing or not undergoing secondary generalization in adult patients with epilepsy with lack of seizure control or intolerance to treatment after at least one trial of an add-on therapy.